| scholarly article | Q13442814 |
| P50 | author | Dirk Dittmer | Q71109132 |
| Jie Xiong | Q85365825 | ||
| Mina C Hosseinipour | Q92921932 | ||
| Sam Phiri | Q114429005 | ||
| P2093 | author name string | Jeannette Lee | |
| Deborah Kamwendo | |||
| Irving Hoffman | |||
| Blossom Damania | |||
| Dan Namarika | |||
| Wolfgang Vahrson | |||
| Albert Mwafongo | |||
| Loreen Chiwoko | |||
| Kristen M Sweet | |||
| Michael Nyirenda | |||
| P2860 | cites work | Global cancer statistics | Q22241238 |
| Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma | Q28242984 | ||
| The tumor microenvironment controls primary effusion lymphoma growth in vivo | Q28272290 | ||
| Antiviral drug susceptibility of human herpesvirus 8 | Q28379288 | ||
| Pathology of rituximab-induced Kaposi sarcoma flare | Q33354623 | ||
| Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda | Q33401242 | ||
| Clinical characteristics and outcomes of HIV-infected children diagnosed with Kaposi sarcoma in Malawi and Botswana | Q33406437 | ||
| A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus | Q33784966 | ||
| Transcription program of human herpesvirus 8 (kaposi's sarcoma-associated herpesvirus). | Q33841257 | ||
| Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities | Q34193400 | ||
| Charting latency transcripts in Kaposi's sarcoma-associated herpesvirus by whole-genome real-time quantitative PCR | Q34340317 | ||
| Sexual transmission and the natural history of human herpesvirus 8 infection | Q34462040 | ||
| Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma | Q34559661 | ||
| Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma | Q34579974 | ||
| Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy | Q34620787 | ||
| Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection | Q34633782 | ||
| High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy | Q35127955 | ||
| Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma | Q35131811 | ||
| Restricted Kaposi's sarcoma (KS) herpesvirus transcription in KS lesions from patients on successful antiretroviral therapy | Q35458156 | ||
| Kaposi's sarcoma: a review of gene expression and ultrastructure of KS spindle cells in vivo | Q35565392 | ||
| Azidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt lymphoma | Q35847814 | ||
| Treatment of Kaposi sarcoma-associated herpesvirus-associated cancers | Q35895560 | ||
| A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa | Q35989731 | ||
| Impact of antiretroviral therapy on the incidence of Kaposi's sarcoma in resource-rich and resource-limited settings | Q36162341 | ||
| Experimental transmission of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) to SCID-hu Thy/Liv mice | Q36375588 | ||
| Recent cancer incidence trends in an observational clinical cohort of HIV-infected patients in the US, 2000 to 2011 | Q36901045 | ||
| Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy | Q37085001 | ||
| Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin | Q37200835 | ||
| Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors | Q37259751 | ||
| Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy | Q37366303 | ||
| KSHV 2.0: a comprehensive annotation of the Kaposi's sarcoma-associated herpesvirus genome using next-generation sequencing reveals novel genomic and functional features | Q37488130 | ||
| Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. | Q37538520 | ||
| Immunohistochemistry in Kaposi's sarcoma | Q37623892 | ||
| Moving forward in HIV-associated cancer. | Q37627688 | ||
| Pervasive transcription of a herpesvirus genome generates functionally important RNAs | Q37634460 | ||
| Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission | Q37684392 | ||
| Kaposi sarcoma associated herpesvirus pathogenesis (KSHV)--an update | Q38114627 | ||
| Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays | Q38305362 | ||
| Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. | Q39172502 | ||
| Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir | Q39594055 | ||
| Array-based transcript profiling and limiting-dilution reverse transcription-PCR analysis identify additional latent genes in Kaposi's sarcoma-associated herpesvirus | Q39729318 | ||
| Hypoxia enhances the phosphorylation and cytotoxicity of ganciclovir and zidovudine in Kaposi's sarcoma-associated herpesvirus infected cells | Q40105402 | ||
| Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo | Q40287215 | ||
| In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma. | Q41839438 | ||
| Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response | Q41956982 | ||
| A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity | Q42624833 | ||
| Real-time quantitative PCR analysis of viral transcription. | Q42639044 | ||
| More on HIV-associated Kaposi's sarcoma | Q42828054 | ||
| Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe | Q43007780 | ||
| Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. | Q43931328 | ||
| A pilot study of cidofovir in patients with kaposi sarcoma | Q44267020 | ||
| Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8. | Q45212214 | ||
| Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma. | Q47367466 | ||
| Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. | Q53347753 | ||
| Prospective stage-stratified approach to AIDS-related Kaposi's sarcoma. | Q54385072 | ||
| Transcription profile of Kaposi's sarcoma-associated herpesvirus in primary Kaposi's sarcoma lesions as determined by real-time PCR arrays | Q73344152 | ||
| HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load | Q81357750 | ||
| Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma | Q83750628 | ||
| P433 | issue | 5 | |
| P304 | page(s) | e01633-14 | |
| P577 | publication date | 2014-09-23 | |
| P1433 | published in | mBio | Q15817061 |
| P1476 | title | Viral profiling identifies multiple subtypes of Kaposi's sarcoma | |
| P478 | volume | 5 |
| Q33887891 | Cancer trials in sub-Saharan Africa: Aligning research and care. |
| Q64263465 | Cell Type-Specific Interferon-γ-mediated Antagonism of KSHV Lytic Replication |
| Q35991165 | Clinical Factors Associated with Long-Term Complete Remission versus Poor Response to Chemotherapy in HIV-Infected Children and Adolescents with Kaposi Sarcoma Receiving Bleomycin and Vincristine: A Retrospective Observational Study |
| Q39190555 | Diagnosis and Treatment of Kaposi Sarcoma |
| Q33814547 | Effect of electrochemotherapy on human herpesvirus 8 kinetics in classic Kaposi sarcoma |
| Q61800540 | Extracellular vesicles from Kaposi Sarcoma-associated herpesvirus lymphoma induce long-term endothelial cell reprogramming |
| Q90434397 | Genome-Wide Identification of Direct RTA Targets Reveals Key Host Factors for Kaposi's Sarcoma-Associated Herpesvirus Lytic Reactivation |
| Q38944679 | HIV-associated malignancies in sub-Saharan Africa: progress, challenges, and opportunities |
| Q54111927 | Human herpesvirus-encoded kinase induces B cell lymphomas in vivo. |
| Q92340148 | In Vivo Models of Oncoproteins Encoded by Kaposi's Sarcoma-Associated Herpesvirus |
| Q59352876 | KSHV viral load and Interleukin-6 in HIV-associated pediatric Kaposi sarcoma-Exploring the role of lytic activation in driving the unique clinical features seen in endemic regions |
| Q89475191 | KSHV-induced ligand mediated activation of PDGF receptor-alpha drives Kaposi's sarcomagenesis |
| Q92129644 | Kaposi Sarcoma Herpesvirus Inflammatory Cytokine Syndrome-like Clinical Presentation in Human Immunodeficiency Virus-infected Children in Malawi |
| Q37173586 | Kaposi Sarcoma of Childhood: Inborn or Acquired Immunodeficiency to Oncogenic HHV-8 |
| Q94012444 | Kaposi sarcoma |
| Q40046587 | Kaposi sarcoma herpesvirus pathogenesis. |
| Q53711383 | Kaposi sarcoma, oral malformations, mitral dysplasia, and scoliosis associated with 7q34-q36.3 heterozygous terminal deletion. |
| Q90319829 | Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Associated Disease in the AIDS Patient: An Update |
| Q92376588 | Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication Interferes with mTORC1 Regulation of Autophagy and Viral Protein Synthesis |
| Q57169056 | Kaposi's Sarcoma-Associated Herpesvirus Nonstructural Membrane Protein pK15 Recruits the Class II Phosphatidylinositol 3-Kinase PI3K-C2α To Activate Productive Viral Replication |
| Q92479600 | Kaposi's Sarcoma-Associated Herpesvirus-Encoded circRNAs Are Expressed in Infected Tumor Tissues and Are Incorporated into Virions |
| Q40400561 | Kaposi's sarcoma in Malawi: a continued problem for HIV-positive and HIV-negative individuals |
| Q59356546 | Mutant Cellular AP-1 Proteins Promote Expression of a Subset of Epstein-Barr Virus Late Genes in the Absence of Lytic Viral DNA Replication |
| Q40116637 | Oral shedding of herpesviruses in HIV-infected patients with varying degrees of immune status |
| Q92278120 | PDGFRA defines the mesenchymal stem cell Kaposi's sarcoma progenitors by enabling KSHV oncogenesis in an angiogenic environment |
| Q53686620 | Pediatric Kaposi sarcoma in context of the HIV epidemic in sub-Saharan Africa: current perspectives. |
| Q60952467 | Quantitative RNAseq analysis of Ugandan KS tumors reveals KSHV gene expression dominated by transcription from the LTd downstream latency promoter |
| Q55338587 | Role of Pattern Recognition Receptors in KSHV Infection. |
| Q90818703 | Runaway Kaposi Sarcoma-associated herpesvirus replication correlates with systemic IL-10 levels |
| Q41932132 | The Kaposi's sarcoma-associated herpesvirus (KSHV) non-structural membrane protein K15 is required for viral lytic replication and may represent a therapeutic target. |
| Q92257146 | Transcriptional and post-transcriptional regulation of viral gene expression in the gamma-herpesvirus Kaposi's sarcoma-associated herpesvirus |
Search more.